[{"id":"b2796697-f53f-4b0f-891f-ff27bfd09451","acronym":"","url":"https://clinicaltrials.gov/study/NCT05852691","created_at":"2023-05-10T21:04:00.257Z","updated_at":"2025-02-25T14:09:43.602Z","phase":"Phase 2","brief_title":"A Study of Tobemstomig + Nab-Paclitaxel Compared With Pembrolizumab + Nab-Paclitaxel in Participants With Previously Untreated, PD-L1-Positive, Locally-Advanced Unresectable or Metastatic Triple-Negative Breast Cancer","source_id_and_acronym":"NCT05852691","lead_sponsor":"Hoffmann-La Roche","biomarkers":" HER-2 • PD-L1 • ER • CD4","pipe":" | ","alterations":" PD-L1 expression","tags":["HER-2 • PD-L1 • ER • CD4"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e PD-L1 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Keytruda (pembrolizumab) • albumin-bound paclitaxel • tobemstomig (RG6139)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 83","initiation":"Initiation: 07/18/2023","start_date":" 07/18/2023","primary_txt":" Primary completion: 12/24/2026","primary_completion_date":" 12/24/2026","study_txt":" Completion: 12/24/2026","study_completion_date":" 12/24/2026","last_update_posted":"2025-02-19"},{"id":"f7fcbd54-143e-4657-9b77-27581b5037f3","acronym":"Morpheus-Liver","url":"https://clinicaltrials.gov/study/NCT04524871","created_at":"2021-01-18T21:40:19.145Z","updated_at":"2025-02-25T15:26:31.453Z","phase":"Phase 1/2","brief_title":"A Study Evaluating the Efficacy and Safety of Multiple Immunotherapy-Based Treatment Combinations in Patients With Advanced Liver Cancers (Morpheus-Liver)","source_id_and_acronym":"NCT04524871 - Morpheus-Liver","lead_sponsor":"Hoffmann-La Roche","biomarkers":" PD-L1","pipe":"","alterations":" ","tags":["PD-L1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Avastin (bevacizumab) • Tecentriq (atezolizumab) • amezalpat (TPST-1120) • Actemra IV (tocilizumab) • tiragolumab (RG6058) • IO-108 • SAR439459 • imdatifan (NKT2152) • muzastotug (ADG126) • tobemstomig (RG6139)"],"overall_status":"Recruiting","enrollment":" Enrollment 518","initiation":"Initiation: 11/01/2020","start_date":" 11/01/2020","primary_txt":" Primary completion: 12/31/2026","primary_completion_date":" 12/31/2026","study_txt":" Completion: 12/31/2026","study_completion_date":" 12/31/2026","last_update_posted":"2025-02-10"},{"id":"5741b2e4-403a-47d5-b489-ab51fac66036","acronym":"","url":"https://clinicaltrials.gov/study/NCT05645692","created_at":"2022-12-09T14:57:54.227Z","updated_at":"2025-02-25T16:39:31.560Z","phase":"Phase 2","brief_title":"A Study Evaluating Different Immunotherapies (LAG-3 and PD-1 With or Without TIGIT, Compared to PD-L1 Alone) in Participants With Untreated Locally Advanced Metastatic Urothelial Cancer","source_id_and_acronym":"NCT05645692","lead_sponsor":"Hoffmann-La Roche","biomarkers":" PD-L1","pipe":"","alterations":" ","tags":["PD-L1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Tecentriq (atezolizumab) • tiragolumab (RG6058) • tobemstomig (RG6139)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 204","initiation":"Initiation: 04/13/2023","start_date":" 04/13/2023","primary_txt":" Primary completion: 12/30/2026","primary_completion_date":" 12/30/2026","study_txt":" Completion: 12/30/2026","study_completion_date":" 12/30/2026","last_update_posted":"2025-02-06"},{"id":"118d6c61-8ca8-4963-a384-4abc48d763da","acronym":"","url":"https://clinicaltrials.gov/study/NCT05419388","created_at":"2022-06-15T16:54:51.817Z","updated_at":"2024-07-02T16:34:37.005Z","phase":"Phase 1/2","brief_title":"A Study of Multiple Doses of RO7247669 in Participants With Previously Untreated Unresectable or Metastatic Melanoma","source_id_and_acronym":"NCT05419388","lead_sponsor":"Hoffmann-La Roche","biomarkers":" PD-L1 • BRAF","pipe":" | ","alterations":" BRAF mutation • BRAF V600","tags":["PD-L1 • BRAF"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e BRAF mutation • BRAF V600"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e tobemstomig (RG6139)"],"overall_status":"Recruiting","enrollment":" Enrollment 80","initiation":"Initiation: 08/15/2022","start_date":" 08/15/2022","primary_txt":" Primary completion: 10/15/2025","primary_completion_date":" 10/15/2025","study_txt":" Completion: 10/15/2025","study_completion_date":" 10/15/2025","last_update_posted":"2024-06-07"},{"id":"cc11874d-5eb7-4a2d-8f41-300686dee487","acronym":"","url":"https://clinicaltrials.gov/study/NCT05775289","created_at":"2023-03-20T20:03:26.021Z","updated_at":"2024-07-02T16:34:59.949Z","phase":"Phase 2","brief_title":"A Study of Tobemstomig Plus Platinum-Based Chemotherapy vs Pembrolizumab Plus Platinum-Based Chemotherapy in Participants With Previously Untreated Non-Small Cell Lung Cancer","source_id_and_acronym":"NCT05775289","lead_sponsor":"Hoffmann-La Roche","biomarkers":" PD-L1","pipe":" | ","alterations":" PD-L1 expression","tags":["PD-L1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e PD-L1 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Keytruda (pembrolizumab) • carboplatin • paclitaxel • pemetrexed • tobemstomig (RG6139)"],"overall_status":"Recruiting","enrollment":" Enrollment 180","initiation":"Initiation: 03/15/2023","start_date":" 03/15/2023","primary_txt":" Primary completion: 03/30/2026","primary_completion_date":" 03/30/2026","study_txt":" Completion: 03/30/2028","study_completion_date":" 03/30/2028","last_update_posted":"2024-05-30"},{"id":"715d1c6b-4590-4d65-b4fb-968075ff03b9","acronym":"","url":"https://clinicaltrials.gov/study/NCT05116202","created_at":"2023-07-21T01:09:41.714Z","updated_at":"2024-07-02T16:35:06.758Z","phase":"Phase 1/2","brief_title":"A Study Evaluating the Efficacy and Safety of Multiple Treatment Combinations in Patients With Melanoma (Morpheus-Melanoma)","source_id_and_acronym":"NCT05116202","lead_sponsor":"Hoffmann-La Roche","biomarkers":" CD4","pipe":"","alterations":" ","tags":["CD4"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Opdivo (nivolumab) • Tecentriq (atezolizumab) • Yervoy (ipilimumab) • tiragolumab (RG6058) • tobemstomig (RG6139)"],"overall_status":"Completed","enrollment":" Enrollment 110","initiation":"Initiation: 02/02/2022","start_date":" 02/02/2022","primary_txt":" Primary completion: 09/22/2023","primary_completion_date":" 09/22/2023","study_txt":" Completion: 03/27/2024","study_completion_date":" 03/27/2024","last_update_posted":"2024-05-01"}]